The global ascorbic acid sector is on track to achieve a valuation of USD 3.0 billion by 2036, accelerating from USD 1.7 billion in 2026 at a CAGR of 5.7%. As per Future Market Insights, expansion is structurally underpinned by the growing demand for vitamin C across pharmaceutical formulations, functional food fortification, and cosmetic active ingredients, combined with the ongoing restructuring of global production capacity. The World Health Organization (WHO) includes ascorbic acid on its Model List of Essential Medicines, validating its status as a foundational healthcare input across 150+ national formularies. This essential medicine designation compels governments and manufacturers to maintain secure supply chains for pharmaceutical-grade ascorbic acid. Simultaneously the regulatory landscape is evolving as the European Food Safety Authority (EFSA) tightens health claim substantiation requirements and China's National Medical Products Administration (NMPA) enforces stricter GMP standards for vitamin API exports.
In March 2024, dsm-firmenich completed the sale and transfer of its 100% equity interest in DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd. to Jingjiang Cosfocus Health Technology Co., Ltd. This divestiture was part of dsm-firmenich's broader strategy to restructure its vitamin portfolio, shifting away from standard commodity-grade production in China to focus on its Quali-C high-quality, low-carbon production site in Dalry, Scotland. FMI opines that this portfolio bifurcation will accelerate the premium-certification trend in Western markets, as pharmaceutical and cosmetic formulators increasingly specify Quali-C or equivalent certified-origin ascorbic acid to meet ESG procurement mandates and EU health claim substantiation requirements.
The competitive landscape in 2024, 2025, and 2026 is defined by capacity restructuring and downstream integration. Northeast Pharmaceutical Group signed a framework agreement in November 2024 to acquire a 70% equity stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., integrating peptide biotechnology with its existing vitamin and API production lines to enhance pharmaceutical-grade ascorbic acid capabilities. Shandong Luwei Pharmaceutical Group was awarded the High-quality Development Benchmark Enterprise Award in February 2025 for its pilot project on comprehensive utilisation of waste from Vitamin C fermentation, establishing a scientific standard for recycling production waste. SEIWA KASEI launched iVC 3GA-green in November 2025, a plant-derived sustainable anti-aging vitamin C ingredient for the cosmetics market. OnScent introduced Acerola Cherry Ferment in January 2025, a natural vitamin C-rich ingredient targeting botanical and organic skincare demand. dsm-firmenich reported in January 2026 that Chinese producers are shifting focus to value over volume, with pricing stabilisation and gradual upward movement after 18 months of volatility. As per FMI, this convergence of Western premium-certification, Chinese value-over-volume pricing, and downstream peptide integration confirms that the ascorbic acid market is transitioning from a commodity-driven price war toward a structurally bifurcated supply architecture.
Future Market Insights projects the ascorbic acid industry to expand at a CAGR of 5.7% from 2026 to 2036, increasing from USD 1.7 Billion in 2026 to USD 3.0 Billion by 2036.
FMI Research Approach: FMI proprietary forecasting model based on WHO Essential Medicines List inclusion, EFSA health claim regulation tracking, and Chinese production capacity monitoring.
FMI analysts perceive the market evolving toward a bifurcated supply architecture where premium-certified Western production (dsm-firmenich Quali-C Dalry) serves pharma and cosmetics, while restructured Chinese producers pursue value-over-volume strategies in food-grade and commodity segments.
FMI Research Approach: dsm-firmenich Jiangshan divestiture and Quali-C retention strategy analysis.
China holds the largest share of the global ascorbic acid market by volume which is supported by the concentration of Northeast Pharmaceutical, Shandong Luwei, CSPC Pharmaceutical, and multiple fermentation-based producers that collectively supply over 80% of global production capacity.
FMI Research Approach: FMI country-level revenue modeling by Chinese API export data and NMPA production license tracking.
The global ascorbic acid market is projected to reach USD 3.0 Billion by 2036.
FMI Research Approach: FMI long-term revenue forecast derived from WHO essential medicine consumption projections and premium-grade certification adoption curves.
The ascorbic acid market includes pharmaceutical-grade ascorbic acid (vitamin C API), food-grade ascorbic acid for fortification and preservation, cosmetic-grade ascorbic acid derivatives, and feed-grade ascorbic acid used across pharmaceutical, food and beverage, personal care, and animal nutrition applications.
FMI Research Approach: FMI market taxonomy aligned with WHO Essential Medicines classification, EFSA nutrition guidelines, and pharmacopoeial API standards (USP, EP, JP).
Globally unique trends include Western premium-portfolio restructuring (dsm-firmenich Jiangshan divestiture/Quali-C retention), Chinese value-over-volume pricing pivot (Q1 2026), and peptide-vitamin integration for pharma-grade applications (Northeast Pharmaceutical/Dingcheng acquisition).
FMI Research Approach: dsm-firmenich Q1 2026 Vitamin Market Update and Northeast Pharmaceutical acquisition tracking.
| Metric | Details |
|---|---|
| Industry Size (2026) | USD 1.7 Billion |
| Industry Value (2036) | USD 3.0 Billion |
| CAGR (2026 to 2036) | 5.7% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research
Strict regulatory requirements combined with high profit margins make Pharmaceutical Grade Ascorbic Acid prominent
Standards of quality and regulatory compliance in the pharmaceuticals industry are non-negotiable and this makes Pharmaceutical Grade Ascorbic Acid a big segment. Certain categories relevant to pharmaceutical manufacturing, such as ethical manufacturing practices, extensive concomitant documentation, additional tests and compliance with various standards, set a high threshold for market entry.
However, after entry, such conditions are compensated by profits, which exceed the food-grade ones, hence making pharmaceutical-grade production more appealing for manufacturers. Measures for quality control such as testing for impurities, metal content and presence of microbiological contaminants, along with validation requirements for the production process, lead to high expenses, however, ensure a high-quality product.
Rising applications of Ascorbic Acid in Food & Beverages due to growing functional food & natural preservatives demand
The food and beverage sector has seen remarkable growth in ascorbic acid use in recent years, due to rising consumer demand for functional foods and natural preservatives. This development is in line with the growing demand for more nutritious foods among buyers. Manufacturers also use ascorbic acid in their products as a vitamin C source and regard it as a naturally derived substitute instead of chemical preservatives.
The wide functionalities of ascorbic acid from beverages and baked goods to meat products have made it an important component of modern food and beverage formulations. Furthermore, as Ascorbic acid helps in shelf life extension, color preservation and product quality enhancement, it has become a widely used ingredient in processed foods, dairy goods and functional beverages.
Granular Ascorbic Acid is preferred in F&B use due to its reduced caking & better dissolution properties
Granular Ascorbic Acid has become the preferred form in food and beverages due to its better handling characteristics. This addresses an important processing issue that manufacturers face with the traditional crystalline form. The granular form reduces caking issues which are involved in both storage and manufacturing processes, thus enabling the smooth production of goods.
Furthermore, its better dissolution properties improve the dispersion of ascorbic acid in different food formulations where evenness and quickness are needed. Granular ascorbic acid also improves dosing accuracy and mixing efficiency, which leads to more consistent final products. All of these benefits lead to reduced cycle times, lower manufacturing costs and better quality of the product. In addition to this, the granular shape form is also less likely to be affected by moisture, which improves storage stability.
The ascorbic acid industry went through many changes in the past few years as applications and consumer preferences evolved. In the early 2000s, Chinese manufacturers disrupted the industry using fermentation technology and building cost-competitive manufacturing plants. This, in turn, led to excess supply and rapid expansion thus leading to price wars. With consistent growth in demand across the pharmaceutical, food and personal care industries, the fluctuations in price have become lesser and stability has come back to the industry.
Moving forward, multiple trends are expected to increase growth. The pandemic has created a shift in demand with consumers paying more attention to preventive healthcare and consuming immune-boosting products. Furthermore, the industry also has the potential to grow with the food and beverage industry as an antioxidant and as a preservative. There is a focus on environmental sustainability, which is steadily becoming an area of concern, thus leading to manufacturers adopting cleaner production technologies, including bio-based processes.
With many manufacturers across the globe, especially in China, the Ascorbic acid market has a fragmented industry structure. The industry has been largely dominated by local manufacturers in China, with some international companies that target specific premium segments.
The presence of numerous manufacturers such as CSPC Pharmaceutical Group, Northeast Pharmaceutical Group, Shandong Luwei and Henan Huaxing indicates the fragmented nature of the industry. In the industrial and feed-grade sectors, these regional companies compete on low cost and high volumes. Due to globalization and the lack of any other major players, China remains the key player in the industry with significant market share.
There are some MNCs operating in the industry, which include DSM-Firmenich and BASF among others. While having a much smaller market share in comparison, they cater to an important segment of pharmaceutical-grade products. These MNCs are not price-driven in competition as they rely more on quality certifications and advanced technology. Food and beverage, pharmaceuticals, cosmetic as well as animal feed industries are fragmented, which add to the lack of concentration in the Ascorbic acid industry. Each of these has its evaluations of quality as well as competition which makes some producers of certain qualities thrive.
With CSPC being among the top ascorbic acid suppliers in China, they are working towards increasing their export market with more competitive pricing as their Hebei Province's vertically integrated production facilities have been successful in cost management. They have also installed fermentation devices to improve productivity and reduce pollution.
NEPG modernized its ascorbic acid manufacturing plant in order to retain its standing as one of the biggest suppliers in China. Their focus is on high-quality ascorbic acid for use in pharmaceuticals. They have also worked towards increasing their export operations and have successfully established their visibility outside China through mobile distribution resources in Southeast Asia and Europe market.
The following table shows the estimated growth rates of the top five markets. These countries are set to exhibit high consumption, recording high CAGRs through 2036.
| Countries | CAGR, 2026 to 2036 |
|---|---|
| China | 5.5% |
| USA | 5.8% |
| Germany | 5.2% |
| India | 6.1% |
| Japan | 5.3% |
The shift of dominance from other nations to China in the industry has been due to China's prominence in both the production and distribution of ascorbic acid. This has been achieved by government support in technology advancements along with low-cost provisioning capabilities. The broad consumer base within China, along with rising disposable income is also allowing for better export capability. With the government's support for the various chemical manufacturing industries, especially in Research & Development, China has been able to maintain this advantage at the international level.
Recently, however, Chinese manufacturers have strongly invested in quality control measures in order to shift the global standards towards the Chinese system. The fragmented nature of the industry which consists of multiple small players ensures healthy competition to increase efficiency and quality. The industry for Ascorbic Acid in the country is projected to exhibit a CAGR of 5.5% during the assessment period and revenue from the sales of the product in the country is expected to reach USD 866.8 million with a market share of 31% by 2035.
The USA has advanced infrastructure that cater to the requirements of ascorbic acid manufacturers. The combination of high-quality standards, along with research and a high level of investment provides the environment for high-quality products. Leading firms within the region have continued to develop an edge within the ascorbic acid supply chain making them competitive.
Nutraceuticals and pharmaceuticals are in high demand, which has, in turn, led to the demand for ascorbic acid. Much of the demand is too high for western companies and so, a significant portion of the overall demand is exported from the various Chinese manufacturers who currently dominate the industry. Due to the attention being paid to drug improvement initiatives, the industry has been growing relatively quickly as well. These trends are leading to a projected value of USD 559.2 million by 2035 with Ascorbic Acid demand calculated to rise at a value CAGR of 5.8% during the forecast period (2025 to 2035) with a value share of 20%.
The Japan Ascorbic acid market has a unique identity owing to its mature personal care and nutraceuticals sectors. With a rapidly aging population and the shift towards preventive medicine, the demand for vitamin C supplements and medicines has been rising constantly in Japan. Beauty and skincare products that have scientific backing are in high demand, which in turn is driving demand for Ascorbic Acid. Recent groundbreaking research regarding the usage of ascorbic acid in cosmetics alongside more complex drug delivery systems is also expected to bolster growth of market.
Given that the Japanese consumers are highly sensitive to quality, manufacturers are now focusing on producing high quality customized ascorbic acid grades and forms. These factors are responsible for the robust projected forecast CAGR of 5.3% from 2025 to 2035, with the country achieving a global value share of 7% in 2035 with a value of USD 195.7 million.
| Segment | Powder / Crystal |
|---|---|
| Main Segment | Form Type |
| Value Share (2036) | 65% |
The powder or crystal form of ascorbic acid has maintained its leadership in the segment due to practical advantages in the supply chain. This form's stability under various environmental conditions decreases degradation during transportation and storage, thus improving the quality of the end-product. Its extended shelf life reduces waste and logistical costs, while the ease of transportation makes it a very economical choice for both manufacturers and distributors.
The powder form's usage in various applications, from direct compression in tablets to easy dissolution in liquid formulations, makes it the preferred form of ascorbic acid. Its ability to be precisely measured and mixed with other ingredients are also reasons for the segment’s continued growth.
| Segment | Reichstein Process |
|---|---|
| Main Segment | Production Metdod |
| Value Share (2036) | 77% |
The Reichstein Process continues to maintain its position as the industry standard for ascorbic acid production, despite being developed decades ago. This process has been continuously refined and optimized, offering manufacturers the perfect balance of efficiency and quality. Its ability to produce consistent, high-quality ascorbic acid at a commercial scale, combined with well-understood process parameters and established quality control measures, makes it a very reliable production method.
The process's predictable outcomes have led to many investments in optimizing and automating the various stages, which has resulted in improved results and reduced production costs. The extensive industry experience with this process has also created a deep understanding of the possible errors and their troubleshooting procedures, making it a dependable choice for large-scale production.
The industry of ascorbic acid has tough competition from both international and local players, with the latter dominating currently. Companies are investing in up-to-date and cutting-edge technologies in order to get an edge over their competitors. Research & Development of new product lines is being prioritized in order to deal with the changing consumer needs as well as changing manufacturing technologies.
The global shift towards sustainable production methods has also become a USP for companies wishing to separate themselves from the fragmented mass of companies fighting for market share.
Strategic and long-lasting partnerships with end-user B2B industries such as pharmaceuticals and food industries are proving to be highly useful in securing and improving the current competitive position of the companies.
Ensuring that the products are certified for quality and are compliant with the relevant regulations offers companies a chance to market their products as premium offerings, which has turned out to be one of the main competitive approaches, especially in developed regions.
Recent Developments
The ascorbic acid market represents revenue generated from the manufacture and sale of vitamin C (L-ascorbic acid) across pharmaceutical, food-grade, cosmetic, and feed-grade applications. The market measures the value of bulk ascorbic acid API, ascorbic acid derivatives (sodium ascorbate, calcium ascorbate, ascorbyl palmitate), and stabilised vitamin C actives sold to pharmaceutical manufacturers, food processors, cosmetic formulators, and animal feed producers.
Inclusions cover pharmaceutical-grade ascorbic acid API (USP, EP, JP grade), food-grade ascorbic acid for fortification and antioxidant preservation, cosmetic-grade stabilised vitamin C derivatives (ascorbyl glucoside, 3-O-ethyl ascorbic acid), feed-grade ascorbic acid for aquaculture and poultry, and certified-origin premium ascorbic acid (Quali-C and equivalent).
Exclusions include finished-dosage vitamin C supplements sold to consumers, multivitamin products where ascorbic acid is a minor component, synthetic intermediate chemicals used in ascorbic acid manufacturing, and natural fruit-derived vitamin C extracts sold as whole-food ingredients.
| Items | Values |
|---|---|
| Quantitative Units (2026) | USD 1.7 Billion |
| Product Type | Pharmaceutical-Grade API, Food-Grade, Cosmetic-Grade Derivatives, Feed-Grade |
| End User | Pharmaceutical, Food and Beverage, Personal Care, Animal Nutrition |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Countries Covered | China, USA, India, Germany, Japan, Scotland/UK, and 30+ countries |
| Key Companies Profiled | dsm-firmenich, Northeast Pharmaceutical, Shandong Luwei, CSPC Pharmaceutical, SEIWA KASEI |
As per Form Type, the industry has been categorized into Powder / Crystal, Granules and Liquid.
As per Production Method, the industry has been categorized into Reichstein Process, Two-step Fermentation and Others.
As per Grade Level, the industry has been categorized into Food Grade, Feed Grade, Pharmaceutical Grade and Industry Grade.
As per Application, the industry has been categorized into Food & Beverages, Animal Feed, Cosmetics & Personal Care, Pharmaceuticals and Industrial Applications.
Industry analysis has been carried out in key countries of North America, Latin America, Western Europe Eastern Europe, Balkans & Baltic, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific and Middle East & Africa.
What is the current global market size for Ascorbic Acid?
The global market is valued at USD 1.7 Billion in 2026, driven by pharmaceutical and cosmetic-grade demand growth and Chinese pricing stabilisation.
What is the projected CAGR for the market over the next 10 years?
The market is projected to grow at a CAGR of 5.7% from 2026 to 2036.
Which regions are experiencing the fastest expansion?
Asia Pacific leads by production volume through Chinese manufacturing dominance, while Europe leads premium-grade growth through dsm-firmenich Quali-C certification and EFSA health claim compliance.
What are the primary market drivers?
WHO essential medicine designation, pharmaceutical and cosmetic-grade certification demand, Chinese value-over-volume pricing restructuring, and EFSA health claim substantiation requirements are the primary growth catalysts.
Who are the leading suppliers in the industry?
dsm-firmenich, Northeast Pharmaceutical, Shandong Luwei, and CSPC Pharmaceutical are key players, differentiating through premium certification (Quali-C), peptide-vitamin integration, and sustainable production processes.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Ascorbic Acid Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
